Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

20070001.TNBC

— · E

4c623dc1-d8aa-556c-b98d-13d8e6dabd90

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.460
  • INTERFERON_ALPHA_RESPONSE+0.410
  • MYC_TARGETS_V1+0.360
  • G2M_CHECKPOINT+0.330
  • PROTEIN_SECRETION+0.330
  • UNFOLDED_PROTEIN_RESPONSE+0.330
  • INFLAMMATORY_RESPONSE+0.320
  • INTERFERON_GAMMA_RESPONSE+0.320
  • ALLOGRAFT_REJECTION+0.300
  • E2F_TARGETS+0.300

Top 10 suppressed

  • ESTROGEN_RESPONSE_EARLY-0.100
  • KRAS_SIGNALING_DN-0.090
  • P53_PATHWAY-0.080
  • BILE_ACID_METABOLISM-0.030
  • FATTY_ACID_METABOLISM-0.030
  • DNA_REPAIR-0.020
  • TGF_BETA_SIGNALING-0.020
  • UV_RESPONSE_DN-0.020
  • ANDROGEN_RESPONSE-0.010
  • APOPTOSIS-0.010

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-CV-7097-01A-11R-2016-07
head-neck@1
——0.859
2SRR35579821
breast-umap@18
—E0.845
3MDT-AP-2865
medullo-epn-umap@date-based
MedMedulloblastoma0.843
4SRR29022839
breast-umap@18
—A0.842
5TCGA-IQ-A61E-01A-22R-A30B-07
head-neck@1
——0.837
6SRR1516056
bladder-landscape@3
——0.836
7SRR1516055
bladder-landscape@3
——0.833
8SRR5088816
melanoma-umap@29
——0.833
9SRR5088815
melanoma-umap@29
——0.832
10AF0A7BAA-D031-4C9F-91B7-7034F2C49D72
brain-umap@2
——0.830

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 38 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.460Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.410Inavolisib— uncovered
MYC_TARGETS_V10.360Inavolisib— uncovered
G2M_CHECKPOINT0.330Inavolisib— uncovered
PROTEIN_SECRETION0.330Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.330Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.320Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.320Idelalisib— uncovered
ALLOGRAFT_REJECTION0.300Idelalisib— uncovered
E2F_TARGETS0.300Inavolisib— uncovered
MITOTIC_SPINDLE0.260Inavolisib— uncovered
HYPOXIA0.250Idelalisib— uncovered
GLYCOLYSIS0.240Inavolisib— uncovered
ANGIOGENESIS0.230Remibrutinib— uncovered
COAGULATION0.230Binimetinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.230Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.220Inavolisib— uncovered
NOTCH_SIGNALING0.220Inavolisib— uncovered
COMPLEMENT0.210Inavolisib— uncovered
KRAS_SIGNALING_UP0.200Inavolisib— uncovered